The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma.
 
Myung-Ju Ahn
No Relationships to Disclose
 
Bo Mi Ku
No Relationships to Disclose
 
Seong Yoon Yi
No Relationships to Disclose
 
Jiae Koh
No Relationships to Disclose
 
Yeon-Hee Bae
No Relationships to Disclose
 
Jong-Mu Sun
No Relationships to Disclose
 
Se-Hoon Lee
No Relationships to Disclose
 
Jin Seok Ahn
No Relationships to Disclose
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca